Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-Host Disease

Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease

Bone Marrow Transplantation volume 37, pages 1143–1147 (2006)Cite this article

Abstract

Antitumor necrosis factor-α antibodies are increasingly being used for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) complicating allogeneic stem cell transplantation. We retrospectively reviewed the outcomes of 16 patients with refractory acute predominantly visceral GVHD treated with combination antithymocyte globulin (ATG), tacrolimus and etanercept +/− mycophenolate mofetil (MMF) at our institution. Overall response rate (CR+PR) was 81%, with median survival post commencing salvage immunosuppression 224 days (range 20–1216 days). In total, eight patients (50%) died, including from progressive GVHD in two cases (13%), infection in five (31%) and relapse of underlying malignancy in one (6%). In comparison to our previous experience of ATG+tacrolimus as treatment for refractory visceral GVHD, both response rate and overall survival were improved with addition of etanercept, with no apparent increase in infectious complications. As such, use of etanercept in combination with ATG +/− MMF for treatment of steroid refractory acute GVHD appears to be associated with high response rates, significant survival and no unexpected toxicity. Further study of this immunosuppression combination in a larger cohort of patients in this setting is indicated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Sullivan K . Graft-versus-host disease. In: Blume K, Forman S, Appelbaum F (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing Ltd: Massachuscetts, 2004, pp 635–664.

    Google Scholar 

  2. Mollee P, Morton A, Irving I, Durrant S . Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid refractory acute graft-versus-host disease developing during cyclosporin prophylaxis. Br J Haematol 2001; 113: 217–223.

    Article  CAS  Google Scholar 

  3. MacMillan M, Weisdorf D, Davies S, DeFor T, Burns L, Ramsay N et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40–46.

    Article  CAS  Google Scholar 

  4. Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller H et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995; 15: 891–894.

    CAS  PubMed  Google Scholar 

  5. Basara N, Kiehl M, Blau W, Romer E, Bischoff M, Schmetzer B et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 2001; 33: 2121–2123.

    Article  CAS  Google Scholar 

  6. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J . Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84: 681–685.

    Article  CAS  Google Scholar 

  7. Andolina M, Rabusin M, Maximova N, Di Leo G . Etanercept in graft-versus-host disease. Bone Marrow Transplant 2000; 26: 929.

    Article  CAS  Google Scholar 

  8. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor-a blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.

    Article  CAS  Google Scholar 

  9. Jacobsohn D, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB . Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74: 119–124.

    Article  Google Scholar 

  10. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFα antibody. Bone Marrow Transplant 2001; 28: 47–49.

    Article  CAS  Google Scholar 

  11. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89: 1352–1359.

    CAS  PubMed  Google Scholar 

  12. Yamane T, Yamamura R, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 2003; 44: 2095–2097.

    Article  CAS  Google Scholar 

  13. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-refractory acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003–1010.

    Article  CAS  Google Scholar 

  14. Pzerpiorka D, Kernan N, Ippoliti C, Papadopoulos E, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    Google Scholar 

  15. Willenbacher W, Basara N, Blau I, Fauser A, Kiehl M . Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820–823.

    Article  CAS  Google Scholar 

  16. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haemat 2004; 124: 777–786.

    Article  CAS  Google Scholar 

  17. Massenkeil G, Rackwitz S, Genvresse I, Rosen B, Dorken B, Arnold R . Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogenic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899–903.

    Article  CAS  Google Scholar 

  18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  19. Uberti J, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Beker M et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 680–687.

    Article  CAS  Google Scholar 

  20. Bogunia-Kubik K . Poymorphisms within the genes encoding TNF-a and TNF-b associate with the incidence of post-transplant complications in recipients of allogeneic hematopoietic stem cell transplants. Arch Immunol Ther Exp 2004; 52: 240–249.

    Google Scholar 

  21. Ho V, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.

    Article  Google Scholar 

  22. Marty F, Lee S, Fahey M, Alyea E, Soiffer R, Antin J et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

    G A Kennedy, J Butler, R Western, J Morton, S Durrant & G R Hill

Authors
  1. G A Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Western
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Durrant
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G R Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G A Kennedy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kennedy, G., Butler, J., Western, R. et al. Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 37, 1143–1147 (2006). https://doi.org/10.1038/sj.bmt.1705380

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705380

Keywords

This article is cited by

Search

Advanced search

Quick links